FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-028									
Estimated average b	ourden									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							` '				' '								
1. Name and Address of Reporting Person* PARVEN ALVIN S						2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC ALXN								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
														X Direct	or		10% Ow	/ner	
(Last)	Last) (First) (Middle)												_	Officer (give title Other (spe below) below)				pecify	
C/O ALEXION PHARMACEUTICALS INC 352 KNOTTER DRIVE						3. Date of Earliest Transaction (Month/Day/Year) 12/09/2005													
					\vdash														
						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)													- 1	,	filed by One	e Rep	orting Perso	n	
CHESHIRE CT 06410													Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)																
		Tab	le I - Non	-Deriv	ative	Se	curitie	s Ac	quired, [Disp	osed c	of, or Be	neficial	ly Owne	d				
1. Title of	Security (Inst	tr. 3)		2. Trans	action		2A. Deem		3.			ities Acquir		5. Amo				7. Nature	
Date				Day/Year)		Execution Date, if any (Month/Day/Year		Code (Instr. 5		Disposed Of (D) (Instr. 3, 5)		str. 3, 4 and	Benefic Owned	Beneficially (I Owned Following (I		r Indirect I str. 4) (of Indirect Beneficial Ownership		
								Code	v	Amount	(A) o (D)	r Price	Reporte Transac (Instr. 3				(Instr. 4)		
		7	able II - I						uired, Di					Owned					
1. Title of	2.	3. Transaction	3A. Deeme	d	4.		5. Num	her	6. Date Exe	rcisa	ble and	7. Title an		8. Price of	9. Number	r of	10.	11. Nature	
Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	Date Execution if any (Month/Day/Year)	Date,	4. Transaction Code (Instr. B)		of		Expiration Date (Month/Day/Year)			Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisable		opiration ate	Title	Amount or Number of Shares						
Option to Purchase Common Stock, par value \$ 0001	\$19.73	12/09/2005			A		7,500		(1)	12	2/09/2015	Common Stock, par value \$.0001	7,500	\$19.73	7,500)	D		

Explanation of Responses:

1. These options will vest quarterly in four equal installments of 1,875 options during the one year period commencing on December 9, 2005 and ending on December 9, 2006.

<u>/s/ Alvin Parven</u> <u>12/13/2005</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.